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Strengths and limitations of this study
 ► Contributes to theoretical developments in public in-
volvement as a quality improvement measure.
 ► Develops an ‘ex-post’ theory of how public involve-
ment can be used to improve front-line services.
 ► This evaluation was unable to get robust data on the 
effects of the public involvement activities on the 
development site projects.
 ► Points to areas for future development such as 
developing mechanisms for measuring the impact 
of public involvement on service improvement 
initiatives.
AbStrACt
Objectives The Royal College of Physician’s (RCP) Future 
Hospital Programme (FHP) set out a blueprint for a radical 
new model of care that put patient experience centre 
stage. This paper reports on the results of an independent 
evaluation of the FHP and focuses on the role public 
patient involvement (PPI) played in these projects. The 
paper explores the perceptions and experiences of those 
involved in the FHP of how PPI was operationalised in this 
context, and develops an ‘ex-post’ programme theory of 
PPI in the FHP. We conclude by assessing the benefits and 
challenges of this work.
Setting Secondary care. The FHP consisted of eight 
clinician-led healthcare improvement hospital development 
sites with two phases.
Participants Development site clinical teams, patient 
representatives, the RCP’s Patient and Carer Network, 
members of the FHP team, and fellows and members of 
the RCP.
Design/methods We conducted an independent 
evaluation of the FHP using FHP documentation and 
data collected specifically for the evaluation: qualitative 
interviews, focus groups and a web-based survey.
results The PPI initiatives set out to develop more 
patient-centred care and improve the patient experience. 
The mechanisms designed to meet these goals were (1) 
a programme of PPI in the development site’s projects, 
(2) a better understanding of patient experience and (3) 
evaluation of patient experience.
Conclusion This evaluation of the FHP identifies some 
key elements that need to be considered when attempting 
to more closely integrate PPI and co-production in service 
re-design. The structure of FHP over two phases enabled 
learning from phase I to be incorporated into phase II. 
Having the PPI representatives closely involved, developing 
communities of practice, and the oversight and measuring 
activities acted as ‘disciplinary structures’ that contributed 
to embedding PPI in the FHP and kept the patient 
experience at the forefront of the improvement initiatives.
bACkgrOunD
The Future Hospital Programme (FHP) 
arose out of the Future Hospital Commission 
(FHC), established by the Royal College of 
Physicians (RCP) in 2012. The FHC was set 
up in a response to the RCP’s Hospitals on 
the Edge Report1 that found “A health system 
ill-equipped to cope with the needs of an 
aging population with increasingly complex 
clinical, care and support needs; hospitals 
struggling to cope with an increase in clinical 
demand; and a systematic failure to deliver 
coordinated, patient-centred care”.1 The 
FHC aimed to, ‘set out a radical new model of 
care’ that put patient experience centre stage, 
“Patient experience must be valued as much 
as clinical effectiveness, and patients must be 
involved in service design and delivery”.2 A 
key part of the FHC was to foster and promote 
patient-centred care, which they defined as 
“individualised, compassionate, holistic and 
collaborative… [and] continuous, care in 
settings appropriate to the patient’s clinical 
and care needs viewed from their perspec-
tive”.2 While there is debate in the litera-
ture over how this concept is and should be 
defined,3 key elements of patient-centred 
care for the FHC were continuity of care, 
reduction in unnecessary moving of patients 
between wards and better integration with 
social care services post-discharge.
To take the recommendations and vision 
of the FHC into practice, the RCP set up the 
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FHP in 2013. The RCP advertised for clinician-led health-
care improvement (HCI) proposals to become FHP devel-
opment sites. The first phase was recruited in 2014 and 
focused on improving care for older and frail patients. 
The second phase was a targeted call on integrated care 
and began in 2016. Each phase included four pilot project 
sites; all had to align their objectives with the FHC prin-
ciples (full details of the FHP have been published else-
where).4 5 The programme concluded in 2017, however, 
the sites continued to work on their quality improvement 
initiatives beyond the end of the FHP. Applicants were 
required to:
 ► Provide details of their projects and how these aligned 
with the principles of the FHC;
 ► Demonstrate involvement of patient representatives 
in design and implementation;
 ► Have a local, board-level executive sponsor.4
The FHP was a multifaceted programme of work that 
acted as a support mechanism for the sites to improve 
front-line services, but it did not provide any additional 
‘transformational’ funding. There were four main ways 
that the FHP supported HCI in the development sites:
Public patient involvement (PPI): one of the main 
elements of the FHP was to foster and support PPI in the 
development sites’ HCI projects working closely with the 
RCP Patient Carer Network (PCN) (established in 2004 to 
give greater patient and carer input into the work of the 
RCP). The aim was to have the patient perspective present 
throughout the projects and involve patient representa-
tives actively in the co-production of the project design 
and implementation.
FHP support structures: the RCP established a FHP team 
with a senior physician appointed as Future Hospital 
Officer for each phase who provided clinical leadership 
and support. Collaborative learning structures were devel-
oped, such as learning events where site teams met and 
shared experiences, training in improvement methodol-
ogies, peer support and creating a community of interest 
(the Future Hospital Partners Network).4 The RCP’s PCN 
also provided support to local lay representatives and 
peer learning opportunities across all sites.
Reporting processes: development sites were required to 
report monthly to the FHP team (both written reports 
and telephone calls). This ensured that the sites main-
tained momentum and received regular feedback.
Data collection and analysis: sites were given training 
sessions provided by the RCP or external experts on data 
analysis, project management and support for collecting 
and interpreting performance metrics and patient expe-
rience data. There was a “focus on measuring the true 
impact of clinically-led improvement or change… [to] 
enable clinical teams to improve patient-centred care and 
outcomes”.4
This paper reports the results of an independent eval-
uation of the FHP and focuses on the role public patient 
involvement (PPI) played. The aims of the paper are 
twofold: to explore the perceptions and experiences of 
the central FHP team, the patient representatives and the 
development site teams of how PPI was operationalised 
in this context; and to develop an ‘ex-post’ programme 
theory of what mechanisms the FHP used to meet its 
goals of developing more patient-centred care and 
consequently improving the patient experience. We will 
conclude by assessing the benefits and challenges of this 
programme.
The terms PPI and co-production are contested. 
Tritter defines PPI as “Ways in which patients can draw 
on their experience and contributors of the public can 
apply their priorities to the evaluation, development, 
organisation and delivery of health services”.6 When 
defining the co-production, it is important to recog-
nise that, in the messy realities of practice, how patients 
and the public participated in the FHP did not always 
conform to one definitional model, but often included 
and straddled different types of practice: from passive 
involvement, such as being consulted about planned 
changes, to more active involvement, such as being 
involved in planning; and, in some cases, co-produc-
tion of initiatives.4 5 Co-production was used in FHP to 
mean, “equal partnerships between patients and physi-
cians in the design of health services”.4 Osborne et al7 
define co-production as “the voluntary or involuntary 
involvement of public service users in any of the design, 
management, delivery and/or evaluation of public 
services”. As has been noted, the concept of co-produc-
tion is very broad and specifically, for the FHP, the key 
element of co-production was service co-design,8 and 
we shall use the term co-production/design to denote 
the form co-production took in the FHP. Definitions 
of healthcare improvement are also contested.9 We 
will define HCI broadly as “better patient experience 
and outcomes achieved through changing provider 
behaviour and organisation through using a systematic 
change method and strategies”.10
There is a growing literature on the role of PPI in 
HCI,6–8 but this remains underexplored compared with 
the use of PPI in other areas, and this paper contributes 
to this developing area. There is a large literature on 
theoretical considerations and topologies of involvement 
and a number of attempts to develop categorisations to 
capture what PPI is6 11 12 and what an ‘ideal type’ might 
be.13 Arnsteins’ ladder of engagement is often quoted as 
one of the first examples of this, where the bottom rung 
is manipulation and the top rung is citizens’ power.14 This 
paper does not attempt to compare or measure PPI in 
the FHP according to abstract standards, but contrib-
utes to the empirical literature on the practice of PPI in 
service re/design and quality improvement. It has been 
noted that although there is a substantial body of theo-
retical literature, there is a gap on how involvement and 
co-production/design is carried out in practice.15 It is 
widely recognised that the context of interventions are 
key,16 and this paper provides an example of a specific 
programme of PPI to add to the literature on exploring 
contextual factors and developing good practice in the 
area of PPI in HCI.
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Table 1 Overview of qualitative data
Number Participants
Focus group 1 9 (7 site patient 
representatives, 2 PCN 
members)
8 With each development 
site team
Between 2 and 5 team 
members
All groups included 
the clinical lead and 
5 out of the 8 groups 
included at least one 
patient representative
Interviews 5 Patient representatives
6 FHP core team
11 Members of RCP 
(including 3 senior 
members)
FHP, Future Hospitals Programme; PCN, Patient Carer Network; 
RCP, Royal College of Physicians.
MethODS
This paper is based on a summative evaluation17 our 
team conducted of the FHP as a programme of HCI. It 
does not consider the specific site improvement proj-
ects nor content of these changes (these are reported 
elsewhere).4 18–25 This paper reports on the perceptions 
and experiences of the central FHP team, the patient 
representatives and the development site teams, of how 
PPI was operationalised in this context and the benefits 
and challenges of this work. Our team became involved 
towards the end of the programme and we did not have 
input in the design of the projects, nor the procedures, 
content and timing for gathering metrics.The challenges 
in doing this kind of research have been discussed in the 
literature26 and this paper reports on what happened in a 
HCI initiative in the real world, not one that took place as 
part of a structured research project. There are a number 
of strengths and limitations with using evaluations as 
research data. The strengths are that it provides informa-
tion on what actually happened in practice and it demon-
strates the workings of PPI embedded in the context 
of shifting priorities and changes in the NHS, such as 
funding and personnel changes. The main weakness is 
that from the data collected by the FHP and our evalu-
ation, it was difficult to ascertain the effects of the PPI 
initiatives on the individual development site projects.
We used a multisource approach using a variety of data 
sources. We analysed data the FHP collected, reviewing 
471 documents from the development sites, including 
monthly, quarterly and annual reports, patient reports, 
learning event presentations, posters, feedback, monthly 
call notes, notes from site visits and personal communi-
cations. Members of the team also attended some of the 
national meetings for the development sites.
We also collected data specifically for the evaluation: 
focus groups, qualitative interviews and a web-based 
survey. Focus groups were conducted with all the devel-
opment site teams, which included the clinical lead and 
at least one patient representative. A further focus group 
was conducted with seven local patient representatives 
and two PCN representatives, in which seven of the eight 
development sites were represented. One-to-one inter-
views were offered to all local patient representatives, four 
were conducted via telephone and one patient repre-
sentative provided a written account. One-to-one inter-
views were conducted with key personnel in the RCP, 17 
individuals either face to face or via telephone, six from 
within the FHP core team and 11 who were indirectly 
involved with the FHP, including three senior members 
(see table 1 for an overview).
A web-based questionnaire was circulated to the devel-
opment site team members including the patient repre-
sentatives, providing another opportunity for team 
members to share their opinions individually. The survey 
used a combination of multiple choice and free-text 
response options, with questions based on the topic guide 
for the focus groups. The survey received 22 responses; 
this included at least one response from each of the eight 
development sites and from a mixture of patient repre-
sentatives and clinicians. (for details see Hepworth et al5). 
The full data and analysis are available in the evaluation 
report,5 evaluations of the individual site projects18–25 and 
the final FHP Report.4
All focus groups and interviews were recorded with 
consent and transcribed verbatim, and a constant 
comparative thematic analysis was used to code the data.27 
Descriptive quantitative statistics were used to analyse 
the multiple-choice responses of the survey. To maintain 
participants’ anonymity, development sites are referred 
to as DS1 to DS8, patient representatives as PR1 to PR6 
and the personnel in the FHP team as RCP1 to RCP17 
(see table 2 for information on the participants who we 
quoted). The manuscript was prepared using the Stan-
dards for Quality Improvement Reporting Excellence 
(SQUIRE 2.0).28
reSultS
The FHC saw ‘patient experience as important as clin-
ical effectiveness’ and that patient-centred care should 
drive the improvement of services.2 This commitment 
underpinned the FHP’s attempt to re-orientate hospital 
provision to be more responsive to patients’ needs rather 
than organised around professional and organisational 
imperatives.4 The FHP aimed to do this by consulting 
with patients and the public and also initiating processes 
and structures to facilitate greater PPI and co-produc-
tion/design of initiatives in the development sites’ HCI 
projects.
As has often been noted in the literature,29 HCI 
programmes seldom start with an explicit programme 
theory, defined as “an explanation of why the effects 
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Table 2 Participant information for those quoted in the 
paper
ID Phase Site Role
PR1 I 5 Patient representative
PR2 I 5 Patient representative
PR3 I 4 Patient representative
PR4 I 3 Patient representative
PR5 II 6 Patient representative
PR6 II 7 Patient representative
DS3 I 3 Clinician
DS8 II 8 Clinician
RCP1 – – FHP team
RCP4 – – FHP team
RCP5 – – Other RCP employee
RCP6 – – FHP team
RCP12 – – FHP team
FHP, Future Hospital Programme; RCP, Royal College of 
Physicians.
observed in a programme are likely to have occurred”.30 
Simply describing interventions does not always ensure 
that they can be replicated or scaled up in other contexts. 
How certain outcomes come about, the underpinning 
social processes and the mechanisms that produce these 
outcomes need theoretical interpretation to aid replica-
tion of the intervention.31 Developing theory can also 
form the basis of ‘theory orientated evaluation’, which 
aims to identify “the rationale and assumptions about 
mechanisms that link programs’ processes and inputs 
to outcomes (both intended and unintended)”.30 In 
order to conduct a form of theory-orientated evalua-
tion, we developed a programme theory of PPI as a HCI 
intervention in the FHP. As the FHP did not set out an 
explicit programme theory at the outset, we constructed 
a form of ‘ex-post theory’.30 We developed this ‘ex-post’ 
programme theory from our analysis of the data we 
gathered as part of the evaluation and the wider FHP 
documentation.
The main goals of the PPI procedures in the FHP were 
to develop more patient-centred care and consequently 
improve the patient experience. The mechanisms 
designed to meet these goals can be broken down into 
three elements:
1. Greater PPI and co-production/design of the initia-
tives: having PPI representatives closely involved in 
the development site teams will keep them focused 
on developing patient-centred care and improving the 
patient experience, so that this is less likely to be over-
looked or marginalised.
2. A better understanding of patient experience: organisa-
tions and professionals may not know what constitutes 
‘good patient experience’. PPI can provide important, 
hitherto, missing information and perspectives on pa-
tient experience that can be fed into service redesign 
alongside operational and clinical information.
3. Evaluating patient experience: using patient experi-
ence data as a key metric for evaluating quality of care 
will re-orientate clinical teams to the importance of 
patient experience and aid the prioritisation of pa-
tient-centred care.
How these mechanisms were operationalised in 
practice and determining the successful aspects of the 
FHP are important for thinking through how PPI can 
be used in service change and improvement and what 
lessons can be learnt for future HCI projects. We have 
presented the results to address each of these three 
mechanisms.
PPI and co-production/design of initiatives
Having PPI representatives closely involved in the devel-
opment site teams was seen as a mechanism to begin to 
involve patients and move towards greater co-produc-
tion/design of services to ensure the continual prioritisa-
tion of patient-centred care. PPI was implemented from 
the start of the FHP. The RCP’s PCN was involved in the 
FHC and setting up the FHP. Each development site had 
at least one local PPI representative within their team, 
and in phase II, sites had to show that they had a PPI 
strategy in place before being chosen. The PPI represen-
tatives were meant to be an integral part of the FHP team 
and be active participants in team meetings and deci-
sion-making processes. The majority (63.6%) of respon-
dents to the development site web-based survey reported 
that their project was partially co-produced/designed 
with patients and 27.3% reported that their projects fully 
involved patients. Co-production/design was limited in 
some sites, particularly in phase I, where some projects 
were already fairly well developed before any PPI took 
place.
Although in each phase the development sites had the 
same remit and operating instructions, it was clear that 
PPI did not happen in the same way and to the same 
degree in each site. Comparing the evidence across site 
reports and phases, there were different levels of involve-
ment and the timings and format of PPI varied. In some 
instances, the involvement was reported to be rather 
‘tokenistic’ and the patient representative’s chance to 
influence service redesign was seen as limited (table 3, 
quote 1).
In some of the sites, the PPI representative had little 
input into setting up the project or its design, but were 
more involved at later stages. Some participants felt they 
were brought in after the main decisions were taken 
(table 3, quotes 2 and 3). However, in some sites, patient 
representatives were more actively involved in setting 
up and co-designing the projects from their inception 
(table 3, quote 4).
The FHP central team reported that from their perspec-
tive, PPI was well embedded in the FHP and this enabled 
more co-production/design of projects (table 3, quote 5).
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Table 3 Levels of involvement and co-production/design of initiatives
Involvement and co-production/design of initiatives
Quote 1 “Well I have done very little. I have, I haven’t had no idea what the patient rep was supposed to do. In my opinion I 
was merely a tick in a box that said you have to have a patient rep”. (PR4)
Quote 2 “It quite frankly is that you don’t start off with asking the patients what they want, you start off usually with some 
enthusiastic usually a clinician, who has an idea about how things might be done better… and the patients are 
asked to contribute to the development of that idea”. (PR5)
Quote 3 “All you ever do is ask them to review what you have done rather than to input into it and you know there are these 
things where you go, hmm, this is not a co-production the patient is not at the heart of the process of the project”. 
(PR6)
Quote 4 “(I was) very involved. We meet monthly with the… team which is an opportunity to share and discuss ongoing 
proposals and ideas or implementation of new approaches to working…. The patient reps are treated with courtesy 
and respect and views are listened to and taken on board. We are considered to be an integral and vitally important 
part of the team”. (PR2)
Quote 5 “Unique to Future Hospital, in comparison to the other programmes of work. So there is lots of ‘oh a patient was 
involved’ tick type activity, throughout the College (RCP), and I think the difference particularly with the phase two 
sites is that there is proper co-production with the patients I hope that they feel that way, it certainly seems at least 
a big step along the route to co-production, than anything else that I have been involved with or seen or heard 
about so far”. (RCP1)
Table 4 Better understanding of patient experience
Quote 1 “It has helped to keep the clinicians grounded, it has helped to keep the focus on patient experience”. (RCP12)
Quote 2 “I am very much of the opinion that individual patients cannot represent patients as a whole unless it is very strange 
or peculiar circumstances. Probably, leaders of some patient organisation or something but even then it is a pretty 
poor sample”. (PR5)
Quote 3 “There is still quite a lot of uncertainty about what your (PPI representative) role is. Are you giving a viewpoint as a 
patient who has experienced that service, so if you like common sense from an individual point of view or are you in 
a representative role are you trying to reflect a broader view of patients let's say who are acutely ill going in through 
a particular hospital. And, that I think hasn’t been worked out nationally we haven’t really got a sort of sense of 
what the, what the major aspects of a patient representative role are”. (RCP12)
Quote 4 “I think that the disappointing thing is that one considers patient experience, to be reflected by a patient 
representative. Because patient experience is so much more than just one person coming in and saying… I think 
the word representative is a very difficult word because I am not sure that (our patient representative) could truly 
represent patients other than having been one… we have 70 000 patients a year, so the question in my mind is, you 
know if we are trying to extrapolate a representation of their experience, then having one person who has their own 
carried experience representing them is difficult”. (DS3)
Quote 5 “If you have a patient representative the… are they a representative of the wider population or are they just bringing 
their own baggage to it, that is a big question and it is a big, you almost have to train people not to bring their 
baggage to the table and that is not easy”. (RCP4)
Quote 6 “Patients will speak more openly with us (PPI representatives) than perhaps they feel they can do with the medical 
or other members of the team”. (PR2) and without their input, “I don’t believe their true voice would have been 
heard. And so some assumptions would have been made as to what the patient needs”. (PR2)
better understanding of patient experience
The FHP sought to get a better understanding of patient 
experience in two main ways. First, the involvement of 
the PPI representatives in the site teams; and second, the 
capture of wider patient experience data in each develop-
ment site. These will be discussed in turn.
The involvement of the PPI representatives in the site 
teams was seen as important by members of the central 
FHP team as a way of keeping the focus of the develop-
ment site teams on patient experience (table 4, quote 1).
However, the role of the PPI representative, what it 
should be and who was an appropriate person to occupy 
this type of role were debated by all FHP participants, and 
there was little consensus on this. The key area of debate 
was who could be said to accurately provide insights into 
the patient experience, and how do we know we are not 
just getting a partial view or views that may not be held by 
the majority of patients? As one site noted: “those that are 
able to meaningfully contribute to system redesign are not 
necessarily representative of the wider population”.4 Under-
pinning these concerns was ambiguity over the concept and 
purpose of being a ‘representative’ and what ‘representa-
tiveness’ meant in practice (table 4, quotes 2 and 3).
A clinician in a development site, while supportive of 
having patients involved, questioned the utility of having a 
specific PPI representative, as they felt this just reflected one 
Protected by copyright.
 o
n
 Septem
ber 12, 2019 at University of Liverpool Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027680 on 12 September 2019. Downloaded from 
6 Frith L, et al. BMJ Open 2019;9:e027680. doi:10.1136/bmjopen-2018-027680
Open access 
Table 5 Metrics on patient experience
Quote 1 “… the patient engagement piece is quite labour intensive, and whether without the Future Hospital Programme 
guiding it… will providers prioritise it (patient engagement) in the same way they would without the Future Hospital 
chasing them and asking them what they are doing on a regular basis…”. (DS8)
Quote 2 “For phase two having watched how the sort of organic coming together, people volunteering option in phase one for 
patient reps, hadn’t really been as effective as I think we initially hoped and that, the rigours of doing FHP alongside 
the day jobs… meant that patient recruitment was often low down on their list and sometimes it took them, a good 
few months to recruit a patient rep…. So for phase two we decided to do a more proactive recruitment campaign 
advertised… So we learnt a lot from phase one, about how to take patient involvement and engagement in the 
development site teams from sort of tokenistic and leaving the teams to do it themselves, to really prescribing what 
we needed and to get the framework in place to”. (RCP6)
individual’s opinion (table 4, quote 4). There was a concern 
over the lack of capacity in PPI and one member of the 
central FHP team felt that training was needed to enable 
PPI representatives to step outside of their own concerns 
and be able to represent the wider group (table 4, quote 5).
A second way of incorporating data on patient expe-
rience in the FHP was the systematic capture of patient 
experience data in each development site.30 Local patient 
and PCN representatives played a key role in organising 
and developing patient experience surveys and other 
types of data gathering such as running focus groups 
or public events. The PPI representatives were involved 
in recruiting, training and supporting volunteers to 
pilot the patient experience surveys, provide feedback, 
propose improvements and develop site-specific tailored 
questionnaires.32 These were seen as one of the successes 
of the FHP, that they were able to get the feedback from 
the wider body of patients and in a more sustained and 
nuanced way. One development site patient representa-
tive spoke about how they were able to get much richer 
and valuable data on patient experience and what patients 
wanted from services (see table 4, quote 6).
Metrics on patient experience
An important part of the FHP was building capacity in 
data collection and its management so that the sites 
could demonstrate the impact of their service changes. 
One of the key elements of this was developing exper-
tise in capturing, measuring and interpreting patient 
experience data. “This metrics orientation provides focus 
and develops a language of ‘measures’ that ‘quantifies’ 
patient care”.4 It was seen as important that the metrics 
captured reflected what was important to patients.4 The 
role of this continual data collection in prioritising PPI 
was seen as crucial to the success of instituting PPI in the 
FHP (table 5, quote 1).
One of the benefits of this continual reporting and 
assessment of progress and the incorporation of a form 
of the ‘Plan-Do-Study-Act’ (PDSA) cycle33 was that the 
FHP’s approach to PPI evolved between the two phases. 
This was an iterative process where lessons were learnt 
and improvements made as the programme progressed. 
Due to problems experienced in phase I, where some 
sites lacked any patient representation for periods of 
time or had recruited individuals who had difficulties 
in contributing to the role, changes were made to the 
application process to be a development site. In phase 
II, “Patient representatives were identified in the applica-
tion and were integral to the interview processes”.4 The 
PCN became involved in the selection of the sites and the 
recruitment for the local site PPI representatives became 
more formalised. The development of the PPI represen-
tatives’ role and the overall strategy and implementation 
over the two phases of the FHP is outlined by a member 
of the FHP team (see table 5, quote 2). Other improve-
ments included providing more support for the devel-
opment site PPI representatives. For example, they were 
given a buddy from the central PCN, and this relationship 
became more formalised in phase II.
DISCuSSIOn
The FHP commitment to involving local patients, PPI repre-
sentatives and PCN members in service design, monitoring 
and evaluation was a new experience for the RCP and the 
PCN.32 It was recognised by all parties that ‘doing’ PPI was 
challenging and required significant commitment on the 
part of all members of the development site teams.
The lack of theoretical consideration of how PPI might 
contribute to service change and create the conditions for 
patient-centred care can make evaluation challenging, and 
the paucity of underpinning theory in this area has been 
noted in the literature.29 30 In order to design, carry out and 
continuously evaluate PPI in HCI projects, having a working 
programme theory can provide clear aims and objectives 
against which to assess whether the PPI mechanisms have 
fulfilled their stated aims and if, and how, PPI as an interven-
tion has worked. How such theoretical underpinnings of PPI 
as an intervention can and should be developed are areas 
that need further investigation. We developed an ‘ex-post 
programme theory’ of PPI as an HCI intervention and 
setting out the goals for this kind of programme is a first step 
to developing ways of assessing these initiatives. Our study 
has shown that more work needs to be done on developing 
appropriate metrics for assessing PPI as a HCI tool.
The initial requirements for sites to have a PPI strategy, 
a patient representative and good links with the PCN were 
important framing mechanisms for the project. This kept 
the focus on patient experience and it was by being a FHP 
development site that this was promoted and sustained. As 
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site members observed, along with all the other require-
ments of both the HCI projects and day-to-day business, it 
would have been easy for PPI to get subsumed. The commu-
nities of learning that the FHP support structures created 
and attending learning events with other sites4 acted as a 
disciplinary structure, a community of practice that kept 
PPI at the forefront of the projects.30 The support and 
endorsement for PPI from a prestigious medical college 
was also a key factor in PPI being seen as an important 
and worthwhile activity. This way of improving practice 
through professional communities and expert reassurance 
has been used in other studies,34 and worked well in the 
FHP, although other studies suggest more mixed evidence 
of their effectiveness.35
A challenge with getting comprehensive information 
on patient experience is that only a few patients were and 
could be involved in the PPI initiatives, and therefore, this 
information could be argued to only partially capture the 
patient experience. Even when sites tried to organise public 
involvement days, these often did not attract much interest 
from patients. Further, concepts of how patient representa-
tives ‘represent’ are contested in PPI.36 Several sites saw the 
role of the patient representatives as a ‘patient voice’ rather 
than providing a representative account of ‘patient expe-
rience’. Hence, the ability to attract a range of patients’ 
views and get wider understanding of patient experience 
was often limited. However, sites generally saw the value 
of including patient representatives in clinical teams and 
reported that they found the contribution of patients 
extremely valuable. Several sites were aiming to increase 
the level of patient input, to help them respond to the 
high levels of changing demand among their population 
groups. Thus, adding extra in-house capacity and devel-
oping arrangements for closer working with patient groups 
was seen as a high priority for future service improvement. 
The work done by the patient representatives—running 
patient surveys, developing and piloting new iterations, and 
exploring qualitative data gathering mechanisms, such as 
interviews and focus groups—helped produce much richer 
information, and site teams used this to both monitor their 
progress and feed into further improvement cycles.
Finally, the FHP was designed to enable sites to instigate 
robust systems for measuring progress and giving the sites 
the skills to set up data gathering structures. ‘Measure-
ment always has consequences’,30 and by having patient 
experience data as a key performance indicator and the 
requirement to report to the central FHP team regularly, 
it ensured both that this remained an important focus for 
the projects, and that the patient representatives had a 
clearly defined and important role.
learning between phases
A strength of the FHP was employing learning from 
phase I into phase II and embedding a PDSA cycle in the 
programme. This meant key changes were made in phase 
II that strengthened PPI: involving the PCN in the process 
of choosing sites, strengthening processes for recruiting 
patient representatives, formalising the buddy system 
between the local representatives and a PCN member, 
and recommending each team have two patient represen-
tatives to share the work and provide support.32
limitations
This was an evaluation5 of an existing and ongoing 
project, and the data and measurement processes were 
not determined by the evaluation team. Thus, this eval-
uation is based on the available data and resources. The 
FHP did not include an impact assessment of the PPI 
activity itself and hence, we were not able to get detailed 
process or quantitative data on the activities undertaken 
by either the local or PCN patient representatives.5 As has 
been noted, assessing the impact of PPI on HCI projects 
is challenging, and embedding key measures of success 
throughout the project would have provided a useful way 
of assessing progress during the FHP. The lack of studies 
on how PPI effects the outcomes of service reconfigura-
tions has been noted in Dalton et al’s review,37 and ways 
to measure the impact of PPI are generally under-re-
searched.38 This is an area that needs further research 
to develop ways of effectively capturing the impact and 
effects of PPI in service design and change. For future 
HCI, our study highlighted the need for improvement 
teams to have a programme theory of how the interven-
tion could work from the offset that includes clear goals 
of the initiative, how concepts such as co-production and 
related concepts such as co-design are defined and subse-
quently employed, what markers of success might look 
like and clear mechanisms for achieving this. By having 
a programme theory to guide setting up the initiative 
and establishing mechanisms of achieving key outcome 
measures, it should be possible to determine the impact 
of PPI in HCI with more accuracy.
COnCluSIOnS
Developing an ethos of co-production in the form of 
co-design, even if this was often moving towards rather 
than fully achieved, was a major success of the FHP. To 
meaningfully embed PPI in HCI projects, it needs to be 
sustained and sustainable, and requires significant invest-
ment in support structures, both centrally and locally, 
plus time and space allocated to enabling decisions to 
be genuinely co-produced. There needs to be geniune 
support from the whole system—organisational buy-in—
so that it becomes a ‘way of doing things’ throughout the 
HCI project and once the initiative is rolled out. Addi-
tionally, there needs to be proper investment of staff time 
and associated costs to deliver real PPI and co-production. 
For example, the project teams need dedicated time for 
meetings to start the design process, rather than involving 
patient representatives when the projects are already set 
up, as this inevitably precludes genuine co-production. 
Demonstrating the impact of PPI in HCI projects is the 
next challenge and there is a need to develop methodol-
ogies that can capture relevant metrics and the nuances 
of involvement. Combining qualitative and quantitative 
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data and embedding collection throughout the project 
can give a more multidimensional picture.26 Attention 
to developing programme theories of PPI in HCI will 
be a key step, and this paper aimed to contribute to this 
debate by developing an ‘ex-post theory’ that could be 
used to suggest ways of developing PPI as an HCI tool.
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